Reports
Global Plaque Psoriasis Treatment Market Size, Share: By Diagnosis Method: Blood Tests, Skin Prick Test, Patch Test, Biopsy, Others; By Treatment Type; By Therapy Type; By Route of Administration; By Drug Type; By Population Type; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Plaque Psoriasis Treatment Market Outlook
The growth of the global plaque psoriasis treatment market size is being driven by the rising prevalence of the condition across the globe. The number of worldwide cases in 2022 was close to 124.89 million. The prevalence of the condition is anticipated to grow at a CAGR of 3% during the forecast period of 2023-2031, likely to reach 163.10 cases by 2031.
Plaque Psoriasis Treatment Market: Introduction
Psoriasis refers to a skin condition which leads to red, inflamed, raised, and itchy skin on different parts of the body. The condition has various types and plaque psoriasis is one of the most common types, affecting more than 8 million Americans every year. About 90% of psoriasis patients suffer from plaque psoriasis, making it the most prevalent type of the condition. Plaque psoriasis is an auto-immune chronic disorder in which the production of new skin cells becomes extremely fast. While the production of new skin cells normally takes place in 28-30 days, the production speeds up and the new skin cells start developing within 3 to 4 days. The replacement of old skin cells with new ones results in the production of plaques over the skin. The increased prevalence of the condition is providing significant impetus to the growth of the plaque psoriasis treatment market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Plaque psoriasis leads to severe red patches or plaques all over the skin, with thick whitish scales which are made of dead skin cells. These scales can occur throughout the body and/or on parts of the body which are mostly dehydrated, like scalp, elbows, lower back, knees, among others. Patients with severe condition also experience these scales on their face, feet, hands, legs, and even genitals, if not controlled timely. These patches are extremely problematic since it causes severe itchiness and even hurts, and the burning sensation can become intense and worse with time. It even becomes difficult for the patient to wear clothes over these patches, leading to perennial discomfort.
As discussed above, the most common symptoms of the condition mostly include scaly patches on the skin, which can painful and irritating. As the condition aggravates, the symptoms can intensify to crack (fissures) in skin and even bleeding in some cases.
The auto-immune disorder does not have a cure yet, but the available treatments are effective and can help relieve the symptoms to some extent, if followed regularly. The exact cause of the disease is not known yet, but genetic factors and immune system play a pivotal role in the development of this condition. Other diseases like Crohn's disease, fatty liver disease, diabetes, and metabolic syndrome can also lead to this skin condition.
Plaque Psoriasis Treatment Market- Epidemiology
Plaque psoriasis mostly happens due to genetic factors, it usually runs in the family. This skin condition can happen to anyone, irrespective of their age or sex, however, if affects some more than the others. People belonging to western regions are more vulnerable to this condition than the others.
The possibility of suffering from plaque psoriasis is also significantly dependent on the lifestyle of an individual. Consumption of alcohol, smoke, and other tobacco-based products can increase the chances of suffering from this disorder. Moreover, being obese can also increase a person’s vulnerability to the condition. Having depression or stress can also worsen this condition, since that mostly leads to the irregularity in the consumption of medicines and lack of self-care. The condition can also be caused due to triggers like reaction of some medicines or severe sunburn.
Plaque Psoriasis Treatment Market Segmentations
The market can be categorised into diagnosis method, treatment type, therapy type, route of administration, drug type, population type, treatment channel, end user, distribution channel, and major regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis Method
- Blood Tests
- Skin Prick Test
- Patch Test
- Biopsy
- Others
Plaque Psoriasis Treatment Market Breakup by Treatment Type
- Biologics Drugs
- Apremilast
- Atanercept
- Infliximab
- Adalimumab
- Ustekinumab
- Secukinumab
- Ixekizumab
- Guselkumab
- Tildrakizumab
- Certolizumab
- Others
- Systemic Drugs
- Methotrexate
- Soriatane
- Otezla
- Sotyktu
- Cyclosporin
- Others
- Phototherapy
- Ultraviolet B (UVB)
- Topical Drugs
- Calcipotriene
- Tazarotene
- Calcineurin Inhibitors
- Roflumilast
- Salicylic Acid
- Others
- Others
Market Breakup by Therapy Type
- Monotherapy
- Combination Therapy
Market Breakup by Route of Administration
- Oral
- Tablets
- Capsules
- Parentals
- Intravenous
- Intramuscular
- Topicals
- Others
Plaque Psoriasis Treatment Market Breakup by Drug Type
- Over the Counter
- Prescription
- Branded
- Generics
Market Breakup by Population Type
- Children
- Adults
- Male
- Female
- Geriatrics
- Male
- Female
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Plaque Psoriasis Treatment Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Plaque Psoriasis Treatment Market- Therapeutic Landscape
The treatments currently available in the plaque psoriasis treatment market can only help in relieving and controlling the symptoms and do not guarantee complete cure from the disease. These treatments must be regularly followed to be effective. If the patient does not follow the regime regularly, then it might not help in managing the symptoms.
- Biological Drugs- These drugs are given via a shot or through a vein in the arm. Biological drugs help in targeting some immune cells and restrict the proteins from causing further inflammation. While these drugs help in relieving the symptoms of plaque psoriasis, these can severely affect the capability of the immune system to fight infections. The most popular biological drugs used in the treatment market include Apremilast, Atanercept, Infliximab, Adalimumab, Ustekinumab, Secukinumab, Ixekizumab, Guselkumab, Tildrakizumab, and Certolizumab, among others.
- Systemic Drugs- These drugs are preferred in the case of severe condition. Systemic drugs work throughout the body and calm the immune system. It also controls the growth of new skin cells, leading to reduced inflammation. The most prominent systemic drugs circulating in the market are Methotrexate, Soriatane, Otezla, Sotyktu, and Cyclosporin, among others. These drugs are quite effective, however, the consumption of these drugs can also cause severe side effects. Some side effects include higher risk of skin cancer, liver disorders, and aggressive thoughts and/or depression, among others.
- Topical Drugs- If the patient is experiencing the initial stage of plaque psoriasis, with just a few patches, then the dermatologist might suggest some topical treatment. These prescription creams, gels, or ointments can be applied directly to the affected area for the prescribed period of time. These can include a combination of exfoliating treatments, with moisturising creams, to get rid of the dead skin and to keep the flaky skin at bay. The dermatologist suggests the treatment on the basis of the severity of the condition. They can either prescribe these drugs to be used individually or in combination. The most common topical drugs prescribed for this condition include Calcipotriene, Tazarotene, Calcineurin Inhibitors, Roflumilast, and Salicylic Acid, among others.
- Phototherapy- Phototherapy, also known as light therapy, is also used to reduce the inflammation and slow down the production of new skin cells in psoriasis patients. This treatment is preferred for patients experiencing mild to severe symptoms, or if they have not responded to any other treatment method. In this method, the affected skin is treated with ultraviolet light, which can help reduce the inflammation and can even clear up the patches completely. The treatment is extremely beneficial but can even increase the risk of developing skin cancer amongst psoriasis patients.
While these treatments can help relieve the symptoms, it is always better to follow preventive measures to avoid worsening the condition further. The patients can practise a healthy diet and regular skin care regime to avoid further damage, along with regular consultation with their doctors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Plaque Psoriasis Treatment Market Scenario
The demand for the treatment market is rapidly rising with the rising number of cases across the globe. Changing lifestyles of people, along with the rising addiction to tobacco-based products, cigarettes, and alcohol, has increased their risk of suffering from this condition. Rising number of obese people is also contributing to the rising prevalence of the disease, especially in North America.
North America is leading the global market with a significant share. While in the developing region, the awareness about the condition is pretty low, developed regions are taking initiatives to boost the awareness about the condition. For instance, August is celebrated as Psoriasis Awareness Month in the United States every year. During this month, the government aims to provide support to those who are affected by this condition and spread awareness about the condition. Such initiatives are leading to higher people opting for diagnosis when they experience any symptom similar symptoms, which results in early detection and timely treatment.
Apart from North America, Europe is also witnessing higher growth due to the rising prevalence of the disease. In the Asia Pacific region, leading countries like Australia and India are also witnessing fast growth due to the rising awareness about the condition and its treatment, aided by government support. Such measures are significantly aiding the growth of the market.
Key Players in the Global Plaque Psoriasis Treatment Market
The major companies working on the drugs and treatment of the condition and investing in the clinical trials include the following:
- Pfizer Inc.
- Abbvie Inc.
- Novartis AG
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- Merck & Co Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- AstraZeneca
- Ampio Pharmaceuticals Inc.
- Eli Lilly and Company
- Novartis International AG
- Sun Pharmaceuticals Industries Ltd.
- Stiefel Laboratories
- UCB S.A.
- LEO Pharma
- Cipla Inc.
- Rowan Bioceuticals
- Glenmark Pharmaceuticals
- Win-Medicare Pvt. Ltd.
- Sanofi S.A.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Type |
|
| Breakup by Therapy Type |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Type |
|
| Breakup by Population Type |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Plaque Psoriasis Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Plaque Psoriasis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Plaque Psoriasis Epidemiology (2016-2031)
5.3 Europe Plaque Psoriasis Epidemiology (2016-2031)
5.4 Asia-Pacific Plaque Psoriasis Epidemiology (2016-2031)
5.5 Latin America Plaque Psoriasis Epidemiology (2016-2031)
5.6 Middle East & Africa Plaque Psoriasis Epidemiology (2016-2031)
6 Global Plaque Psoriasis Treatment Market Overview
6.1 Global Plaque Psoriasis Treatment Market Historical Value (2016-2022)
6.2 Global Plaque Psoriasis Treatment Market Forecast Value (2023-2031)
7 Global Plaque Psoriasis Treatment Market Landscape
7.1 Plaque Psoriasis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
8 Plaque Psoriasis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Plaque Psoriasis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Plaque Psoriasis Treatment Market Segmentation
11.1 Global Plaque Psoriasis Treatment Market by Diagnosis Method
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Skin Prick Test
11.1.4 Patch Test
11.1.5 Biopsy
11.1.6 Others
11.2 Global Plaque Psoriasis Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Biologics Drugs
11.2.2.1 Apremilast
11.2.2.2 Atanercept
11.2.2.3 Infliximab
11.2.2.4 Adalimumab
11.2.2.5 Ustekinumab
11.2.2.6 Secukinumab
11.2.2.7 Ixekizumab
11.2.2.8 Guselkumab
11.2.2.9 Tildrakizumab
11.2.2.10 Certolizumab
11.2.2.11 Others
11.2.3 Systemic Drugs
11.2.3.1 Methotrexate
11.2.3.2 Soriatane
11.2.3.3 Otezla
11.2.3.4 Sotyktu
11.2.3.5 Cyclosporin
11.2.3.6 Others
11.2.4 Phototherapy
11.2.4.1 Ultraviolet B (UVB)
11.2.5 Topical Drugs
11.2.5.1 Calcipotriene
11.2.5.2 Tazarotene
11.2.5.3 Calcineurin inhibitors
11.2.5.4 Roflumilast
11.2.5.5 Salicylic acid
11.2.5.6 Others
11.2.6 Others
11.3 Global Plaque Psoriasis Treatment Market by Therapy Type
11.3.1 Market Overview
11.3.2 Monotherapy
11.3.3 Combination Therapy
11.4 Global Plaque Psoriasis Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.2.1 Tablets
11.4.2.2 Capsules
11.4.3 Parentals
11.4.3.1 Intravenous
11.4.3.2 Intramuscular
11.4.4 Topicals
11.4.5 Others
11.5 Global Plaque Psoriasis Treatment Market by Drug Type
11.5.1 Market Overview
11.5.2 Over the Counter
11.5.3 Prescription
11.5.3.1 Branded
11.5.3.2 Generics
11.6 Global Plaque Psoriasis Treatment Market by Population Type
11.6.1 Market Overview
11.6.2 Children
11.6.3 Adults
11.6.3.1 Male
11.6.3.2 Female
11.6.4 Geriatrics
11.6.4.1 Male
11.6.4.2 Female
11.7 Global Plaque Psoriasis Treatment Market by Treatment Channel
11.7.1 Market Overview
11.7.2 Public
11.7.3 Private
11.8 Global Plaque Psoriasis Treatment Market by End User
11.8.1 Market Overview
11.8.2 Hospitals
11.8.3 Specialty Clinics
11.8.4 Homecare Settings
11.8.5 Others
11.9 Global Plaque Psoriasis Treatment Market by Distribution Channel
11.9.1 Market Overview
11.9.2 Hospital Pharmacy
11.9.3 Retail Pharmacy
11.9.4 Online Pharmacy
11.9.5 Others
11.10 Global Plaque Psoriasis Treatment Market by Region
11.10.1 Market Overview
11.10.2 North America
11.10.3 Europe
11.10.4 Asia Pacific
11.10.5 Latin America
11.10.6 Middle East and Africa
12 North America Plaque Psoriasis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Plaque Psoriasis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Plaque Psoriasis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Plaque Psoriasis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Plaque Psoriasis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Abbvie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Boehringer Ingelheim International GmbH.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Merck & Co Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Sun Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Teva Pharmaceuticals Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 AstraZeneca
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Ampio Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Novartis International AG
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Sun Pharmaceuticals Industries Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Stiefel Laboratories
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 UCB S.A.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 LEO Pharma
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Cipla Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Rowan Bioceuticals
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Glenmark Pharmaceuticals
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Win-Medicare Pvt. Ltd.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
23.21 Sanofi S.A.
23.21.1 Financial Analysis
23.21.2 Product Portfolio
23.21.3 Demographic Reach and Achievements
23.21.4 Mergers and Acquisitions
23.21.5 Certifications
24 Plaque Psoriasis Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The number of plaque psoriasis cases was close to 124.89 million in 2022.
The prevalence of the condition is likely to grow at a CAGR of 3.00% during the forecast period of 2023-2031. The number of cases are likely to reach close to 163.10 million by 2031.
The growth of the market is driven by the rising prevalence of the disease, rising population of obese people, growing addiction to cigarettes and alcohol, and sun damage, among others.
The rising awareness about the condition, along with the readily available treatments, acts as key trends for the market.
The diagnosis methods can be categorised into blood tests, skin prick test, patch test, and biopsy, among others.
The condition is treated with biological drugs, systemic drugs, and topical drugs. Apart from drugs, phototherapy is also used to treat the patches.
The therapy types used for plaque psoriasis include monotherapy and combination therapy.
The routes of administration include oral, parentals, and topicals, among others.
The population type can be categorised into children, adults, and geriatrics.
The treatment channels in the market include private and public channels.
The end-user segments include hospitals, specialty clinics, and homecare settings, among others.
The distribution channels in the market include hospital pharmacy, retail pharmacy, and online pharmacy, among others.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The key players in the market include Pfizer Inc., Abbvie Inc., Novartis AG, Amgen Inc., Boehringer Ingelheim International GmbH., Merck & Co Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca, Ampio Pharmaceuticals Inc., Eli Lilly and Company, Novartis International AG, Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories, UCB S.A., LEO Pharma, Cipla Inc., Rowan Bioceuticals, Win-Medicare Pvt. Ltd., Sanofi S.A., and Glenmark Pharmaceuticals.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER